SAREPTA THERAPEUTICS INC (SRPT) Fundamental Analysis & Valuation

NASDAQ:SRPT • US8036071004

Current stock price

23.23 USD
+1.1 (+4.97%)
At close:
22.88 USD
-0.35 (-1.51%)
After Hours:

This SRPT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SRPT Profitability Analysis

1.1 Basic Checks

  • SRPT had negative earnings in the past year.
  • SRPT had a negative operating cash flow in the past year.
  • In the past 5 years SRPT reported 4 times negative net income.
  • In the past 5 years SRPT always reported negative operating cash flow.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M -600M

1.2 Ratios

  • The Return On Assets of SRPT (-21.30%) is better than 74.85% of its industry peers.
  • With a Return On Equity value of -62.55%, SRPT perfoms like the industry average, outperforming 55.90% of the companies in the same industry.
Industry RankSector Rank
ROA -21.3%
ROE -62.55%
ROIC N/A
ROA(3y)-10.59%
ROA(5y)-13.51%
ROE(3y)-36.51%
ROE(5y)-67.48%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • Looking at the Gross Margin, with a value of 69.33%, SRPT is in the better half of the industry, outperforming 79.88% of the companies in the same industry.
  • In the last couple of years the Gross Margin of SRPT has declined.
  • The Profit Margin and Operating Margin are not available for SRPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.57%
GM growth 5Y-4.72%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. SRPT Health Analysis

2.1 Basic Checks

  • SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SRPT has been increased compared to 1 year ago.
  • Compared to 5 years ago, SRPT has more shares outstanding
  • SRPT has a better debt/assets ratio than last year.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • Based on the Altman-Z score of -0.69, we must say that SRPT is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -0.69, SRPT perfoms like the industry average, outperforming 54.93% of the companies in the same industry.
  • A Debt/Equity ratio of 0.73 indicates that SRPT is somewhat dependend on debt financing.
  • SRPT's Debt to Equity ratio of 0.73 is on the low side compared to the rest of the industry. SRPT is outperformed by 72.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF N/A
Altman-Z -0.69
ROIC/WACCN/A
WACC8.25%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B 1.5B

2.3 Liquidity

  • SRPT has a Current Ratio of 2.32. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.32, SRPT is not doing good in the industry: 73.50% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.48 indicates that SRPT should not have too much problems paying its short term obligations.
  • SRPT has a Quick ratio of 1.48. This is amonst the worse of the industry: SRPT underperforms 80.85% of its industry peers.
Industry RankSector Rank
Current Ratio 2.32
Quick Ratio 1.48
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. SRPT Growth Analysis

3.1 Past

  • SRPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -391.67%.
  • The Revenue has grown by 15.58% in the past year. This is quite good.
  • The Revenue has been growing by 32.41% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-391.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-362%
Revenue 1Y (TTM)15.58%
Revenue growth 3Y33.07%
Revenue growth 5Y32.41%
Sales Q2Q%-32.73%

3.2 Future

  • The Earnings Per Share is expected to grow by 20.10% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, SRPT will show a decrease in Revenue. The Revenue will decrease by -7.26% on average per year.
EPS Next Y145.42%
EPS Next 2Y52.38%
EPS Next 3Y31.54%
EPS Next 5Y20.1%
Revenue Next Year-18.84%
Revenue Next 2Y-17.93%
Revenue Next 3Y-12.16%
Revenue Next 5Y-7.26%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

4

4. SRPT Valuation Analysis

4.1 Price/Earnings Ratio

  • SRPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 7.69 indicates a rather cheap valuation of SRPT.
  • Based on the Price/Forward Earnings ratio, SRPT is valued cheaper than 98.45% of the companies in the same industry.
  • SRPT is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.05, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 7.69
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • SRPT's earnings are expected to grow with 31.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.38%
EPS Next 3Y31.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SRPT Dividend Analysis

5.1 Amount

  • No dividends for SRPT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SRPT Fundamentals: All Metrics, Ratios and Statistics

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (4/2/2026, 8:00:01 PM)

After market: 22.88 -0.35 (-1.51%)

23.23

+1.1 (+4.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-04
Inst Owners89.94%
Inst Owner Change0%
Ins Owners5.12%
Ins Owner Change9.79%
Market Cap2.44B
Revenue(TTM)2.20B
Net Income(TTM)-713.41M
Analysts68.48
Price Target30.27 (30.31%)
Short Float %22.99%
Short Ratio7.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-57.12%
Min EPS beat(2)-213.05%
Max EPS beat(2)98.8%
EPS beat(4)2
Avg EPS beat(4)-85.92%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)5
Avg EPS beat(8)217.73%
EPS beat(12)8
Avg EPS beat(12)382.89%
EPS beat(16)10
Avg EPS beat(16)274.39%
Revenue beat(2)2
Avg Revenue beat(2)13.2%
Min Revenue beat(2)10.8%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)11.58%
Min Revenue beat(4)6.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)7.41%
Revenue beat(12)10
Avg Revenue beat(12)6.28%
Revenue beat(16)13
Avg Revenue beat(16)4.84%
PT rev (1m)-2.11%
PT rev (3m)0.41%
EPS NQ rev (1m)-12.39%
EPS NQ rev (3m)237.62%
EPS NY rev (1m)0%
EPS NY rev (3m)28.6%
Revenue NQ rev (1m)0.66%
Revenue NQ rev (3m)26.07%
Revenue NY rev (1m)1.72%
Revenue NY rev (3m)10.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.69
P/S 1.11
P/FCF N/A
P/OCF N/A
P/B 2.14
P/tB 2.19
EV/EBITDA N/A
EPS(TTM)-6.65
EYN/A
EPS(NY)3.02
Fwd EY13%
FCF(TTM)-3
FCFYN/A
OCF(TTM)-1.96
OCFYN/A
SpS20.94
BVpS10.86
TBVpS10.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.3%
ROE -62.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.33%
FCFM N/A
ROA(3y)-10.59%
ROA(5y)-13.51%
ROE(3y)-36.51%
ROE(5y)-67.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.57%
GM growth 5Y-4.72%
F-Score3
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 246.73%
Cap/Sales 5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.32
Quick Ratio 1.48
Altman-Z -0.69
F-Score3
WACC8.25%
ROIC/WACCN/A
Cap/Depr(3y)277.68%
Cap/Depr(5y)204.92%
Cap/Sales(3y)6.58%
Cap/Sales(5y)5.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-391.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-362%
EPS Next Y145.42%
EPS Next 2Y52.38%
EPS Next 3Y31.54%
EPS Next 5Y20.1%
Revenue 1Y (TTM)15.58%
Revenue growth 3Y33.07%
Revenue growth 5Y32.41%
Sales Q2Q%-32.73%
Revenue Next Year-18.84%
Revenue Next 2Y-17.93%
Revenue Next 3Y-12.16%
Revenue Next 5Y-7.26%
EBIT growth 1Y-325.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year193.88%
EBIT Next 3Y31.21%
EBIT Next 5Y17.55%
FCF growth 1Y10.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.15%
OCF growth 3YN/A
OCF growth 5YN/A

SAREPTA THERAPEUTICS INC / SRPT Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SRPT.


Can you provide the valuation status for SAREPTA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Fairly Valued.


Can you provide the profitability details for SAREPTA THERAPEUTICS INC?

SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 1 / 10.


How financially healthy is SAREPTA THERAPEUTICS INC?

The financial health rating of SAREPTA THERAPEUTICS INC (SRPT) is 2 / 10.


What is the expected EPS growth for SAREPTA THERAPEUTICS INC (SRPT) stock?

The Earnings per Share (EPS) of SAREPTA THERAPEUTICS INC (SRPT) is expected to grow by 145.42% in the next year.